Showing 1011-1020 of 5128 results for "".
- Analysis: Women, Minorities Underrepresented in Psoriasis Researchhttps://practicaldermatology.com/news/analysis-women-minorities-underrepresented-in-psoriasis-research/2462215/A new analysis suggested that women and minorities are consistently underrepresented in the psoriasis and hidradenitis suppurativa (HS) medical literature. "Ensuring clinical trial populations reflect the racial, ethnic, and sex makeup of patient populations is important for
- Researchers Identify Factors Limiting New Treatment Decisions for HShttps://practicaldermatology.com/news/factors-affecting-treatment-selection-among-patients-with-hidradenitis-suppurativa/2462211/Researchers seeking to address the gap between evidence-based guidelines and clinical practice in the treatment of hidradenitis suppurativa (HS) have identified several factors influencing patient decision-making. The open-ended, two-center study, conducted through open-ended interviews
- Upadacitinib in Atopic Dermatitis: New Safety Data Encourages Practitioners and Patientshttps://practicaldermatology.com/news/long-term-safety-of-upadacitinib-in-atopic-dermatitis-5-year-analysis-unveils-encouraging-results/2462210/A recent analysis reveals that upadacitinib, an oral Janus kinase 1 (JAK1) inhibitor, maintains its safety profile over a span of 5 years, aiding individuals
- Novartis Set to Acquire Calypso Biotech, Focused on IL-15 Targeted Therapieshttps://practicaldermatology.com/news/novartis-set-to-acquire-calypso-biotech-focused-on-il-15-targeted-therapies/2462204/European-based biotech manufacturer Calypso has entered into an agreement to be acquired by Novartis, according to a press release. "We are excited for this transaction with Novartis," Calypso CEO and Founder Alain Vicari said in a news release. "As part of the
- Co-occurring Autistic Spectrum Disorder Mediates ADHD on Atopic Dermatitis, Acnehttps://practicaldermatology.com/news/co-occurring-asd-mediates-impact-of-adhd-on-atopic-dermatitis-and-acne-a-retrospective-cohort-study/2462200/Both male and females who were diagnosed with attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) showed different risks for acne and eczema, according to a study. "Our study is the first to examine the association between ASD, ADHD, and two of the most commo
- Lower Extremity Lymphedema Linked with Increased Risk for Skin Cancerhttps://practicaldermatology.com/news/lower-extremity-lymphedema-linked-with-increased-risk-for-skin-cancer/2462193/New research suggests that patients with lower extremity lymphedema are at an increased risk for skin cancer. Researchers writing in Mayo Clinic Proceedings enrolled more than 4,400
- AI in Action: Almirall, Barcelona Supercomputing Center, and Nostrum Biodiscovery Seek New Dermatologic Therapies via AIhttps://practicaldermatology.com/news/ai-in-action-almirall-barcelona-supercomputing-center-bsc-and-nostrum-biodiscovery-seek-new-dermatologic-therapies-via-ai/2462171/Almirall S.A. (BME: ALM), Barcelona Supercomputing Center-Centro Nacional de Supercomputación (BSC-CNS) and Nostrum Biodiscovery are joining forces to explore artificial intelligence (AI) and machine learning (ML) generative approaches to design new protein-protein modulators for dermatolo
- Shmuel Gov Named COO of Strata Skin Scienceshttps://practicaldermatology.com/news/shmuel-gov-named-coo-at-strata-skin-sciences/2462169/Shmuel Gov is the new Chief Operating Officer (COO) of STRATA Skin Sciences. The Company has also hired Dr. Amandeep Kaur as Vice President of Marketing and Business Growth. Mr. Gov brings more than 30 years of industry experience in medical device business, operations, and R&
- AD Pipeline Watch: Escient Pharmaceuticals Initiates Proof-of-Concept Study of EP262, a First-in-Class Oral MRGPRX2 Antagonisthttps://practicaldermatology.com/news/ad-pipeline-watch-escient-pharmaceuticals-initiates-proof-of-concept-study-of-ep262-a-first-in-class-oral-mrgprx2-antagonist/2462155/The first subject has been dosed in EASE, a Phase 2a clinical proof-of-concept study of Escient Pharmaceuticals’ EP262 in atopic dermatitis (AD). By blocking activation of MRGPRX2 and degranulation of mast cells, EP262 has the potential to effectively treat multiple mast cell medi
- Can a New Bacteriocin Thwart Antibiotic Resistance?https://practicaldermatology.com/news/can-a-new-bacteriocin-thwart-antibiotic-resistance/2462150/A new bacteriocin in a very common skin bacterium may inhibit the growth of antibiotic-resistant bacteria, new research suggests. The research group for child and youth health at UiT The Arctic University of Norway has studied bacter